4 research outputs found
Riverside, Illinois reconstruction within the historic landscape
Master of ScienceLandscape ArchitectureUniversity of Michiganhttp://deepblue.lib.umich.edu/bitstream/2027.42/114810/1/39015003271890.pdfhttp://deepblue.lib.umich.edu/bitstream/2027.42/114810/2/39015003271890.pd
Requirements for angiology/vascular medicine.
Journal Articleinfo:eu-repo/semantics/publishe
Guidance for the Management of Patients with Vascular Disease or Cardiovascular Risk Factors and COVID-19: Position Paper from VAS-European Independent Foundation in Angiology/Vascular Medicine.
COVID-19 is also manifested with hypercoagulability, pulmonary intravascular coagulation, microangiopathy, and venous thromboembolism (VTE) or arterial thrombosis. Predisposing risk factors to severe COVID-19 are male sex, underlying cardiovascular disease, or cardiovascular risk factors including noncontrolled diabetes mellitus or arterial hypertension, obesity, and advanced age. The VAS-European Independent Foundation in Angiology/Vascular Medicine draws attention to patients with vascular disease (VD) and presents an integral strategy for the management of patients with VD or cardiovascular risk factors (VD-CVR) and COVID-19. VAS recommends (1) a COVID-19-oriented primary health care network for patients with VD-CVR for identification of patients with VD-CVR in the community and patients' education for disease symptoms, use of eHealth technology, adherence to the antithrombotic and vascular regulating treatments, and (2) close medical follow-up for efficacious control of VD progression and prompt application of physical and social distancing measures in case of new epidemic waves. For patients with VD-CVR who receive home treatment for COVID-19, VAS recommends assessment for (1) disease worsening risk and prioritized hospitalization of those at high risk and (2) VTE risk assessment and thromboprophylaxis with rivaroxaban, betrixaban, or low-molecular-weight heparin (LMWH) for those at high risk. For hospitalized patients with VD-CVR and COVID-19, VAS recommends (1) routine thromboprophylaxis with weight-adjusted intermediate doses of LMWH (unless contraindication); (2) LMWH as the drug of choice over unfractionated heparin or direct oral anticoagulants for the treatment of VTE or hypercoagulability; (3) careful evaluation of the risk for disease worsening and prompt application of targeted antiviral or convalescence treatments; (4) monitoring of D-dimer for optimization of the antithrombotic treatment; and (5) evaluation of the risk of VTE before hospital discharge using the IMPROVE-D-dimer score and prolonged post-discharge thromboprophylaxis with rivaroxaban, betrixaban, or LMWH
Guidance for the Management of Patients with Vascular Disease or Cardiovascular Risk Factors and COVID-19: Position Paper from VAS-European Independent Foundation in Angiology/Vascular Medicine
COVID-19 is also manifested with hypercoagulability, pulmonary
intravascular coagulation, microangiopathy, and venous thromboembolism
(VTE) or arterial thrombosis. Predisposing risk factors to severe
COVID-19 are male sex, underlying cardiovascular disease, or
cardiovascular risk factors including noncontrolled diabetes mellitus or
arterial hypertension, obesity, and advanced age. The VAS-European
Independent Foundation in Angiology/Vascular Medicine draws attention to
patients with vascular disease (VD) and presents an integral strategy
for the management of patients with VD or cardiovascular risk factors
(VD-CVR) and COVID-19. VAS recommends (1) a COVID-19-oriented primary
health care network for patients with VD-CVR for identification of
patients with VD-CVR in the community and patients' education for
disease symptoms, use of eHealth technology, adherence to the
antithrombotic and vascular regulating treatments, and (2) close medical
follow-up for efficacious control of VD progression and prompt
application of physical and social distancing measures in case of new
epidemic waves. For patients with VD-CVR who receive home treatment for
COVID-19, VAS recommends assessment for (1) disease worsening risk and
prioritized hospitalization of those at high risk and (2) VTE risk
assessment and thromboprophylaxis with rivaroxaban, betrixaban, or
low-molecular-weight heparin (LMWH) for those at high risk. For
hospitalized patients with VD-CVR and COVID-19, VAS recommends (1)
routine thromboprophylaxis with weight-adjusted intermediate doses of
LMWH (unless contraindication); (2) LMWH as the drug of choice over
unfractionated heparin or direct oral anticoagulants for the treatment
of VTE or hypercoagulability; (3) careful evaluation of the risk for
disease worsening and prompt application of targeted antiviral or
convalescence treatments; (4) monitoring of D-dimer for optimization of
the antithrombotic treatment; and (5) evaluation of the risk of VTE
before hospital discharge using the IMPROVE-D-dimer score and prolonged
post-discharge thromboprophylaxis with rivaroxaban, betrixaban, or LMWH